

Andrew Bottomley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6729707/publications.pdf>

Version: 2024-02-01

69
papers

7,078
citations

76326

40
h-index

98798

67
g-index

71
all docs

71
docs citations

71
times ranked

8946
citing authors

#	ARTICLE	IF	CITATIONS
1	Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30. <i>Quality of Life Research</i> , 2022, 31, 877-888.	3.1	0
2	Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. <i>European Journal of Cancer</i> , 2022, 170, 1-9.	2.8	6
3	Developing Symptom Lists for People with Cancer Treated with Targeted Therapies. <i>Targeted Oncology</i> , 2021, 16, 95-107.	3.6	8
4	Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. <i>European Journal of Haematology</i> , 2021, 106, 697-707.	2.2	1
5	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
6	SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. <i>BMJ Open</i> , 2021, 11, e045105.	1.9	65
7	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	2.8	36
8	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , 2020, 7, 668-675.	1.6	5
9	Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1333-1341.	1.3	1
10	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. <i>Lancet Oncology</i> , The, 2020, 21, e83-e96.	10.7	180
11	Current state of quality of life and patient-reported outcomes research. <i>European Journal of Cancer</i> , 2019, 121, 55-63.	2.8	83
12	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 116, 190-198.	2.8	22
13	Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. <i>Lancet Oncology</i> , The, 2019, 20, e685-e698.	10.7	80
14	Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 483.	7.4	507
15	Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. <i>BMJ Open</i> , 2018, 8, e019117.	1.9	45
16	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. <i>Lancet Oncology</i> , The, 2018, 19, e459-e469.	10.7	66
17	Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. <i>Clinical Trials</i> , 2018, 15, 624-630.	1.6	42
18	Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials. <i>Cancer</i> , 2018, 124, 3409-3416.	4.1	60

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	10.7	91
20	A prospective study to validate the Polish language version of the European Organisation for Research and Treatment of Cancer (EORTC) Colorectal Liver Metastases (QLQ-LMC21) module. <i>European Journal of Oncology Nursing</i> , 2017, 29, 148-154.	2.1	4
21	Making Advances in Quality of Life Studies in Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 659-661.	0.8	8
22	A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials. <i>European Journal of Cancer</i> , 2017, 83, 166-176.	2.8	27
23	A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy. <i>Annals of Palliative Medicine</i> , 2017, 6, S223-S232.	1.2	15
24	The use of EORTC measures in daily clinical practice—A synopsis of a newly developed manual. <i>European Journal of Cancer</i> , 2016, 68, 73-81.	2.8	75
25	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. <i>Lancet Oncology</i> , The, 2016, 17, e510-e514.	10.7	158
26	The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv391.	6.3	28
27	The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 2808-2819.	2.8	105
28	Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development. <i>Cancer</i> , 2015, 121, 4300-4323.	4.1	52
29	Health-related quality of life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). <i>Cancer</i> , 2015, 121, 2933-2941.	4.1	72
30	Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2166-2175.	1.6	112
31	Validation of the Polish version of the EORTC QLQ-OV28 module for the assessment of health-related quality of life in women with ovarian cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 157-163.	1.4	8
32	A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. <i>Cancer</i> , 2014, 120, 302-311.	4.1	168
33	An international phase 3 trial in head and neck cancer: Quality of life and symptom results. <i>Cancer</i> , 2014, 120, 390-398.	4.1	36
34	Validation of the Polish version of the EORTC QLQ-BM22 module for the assessment of health-related quality of life in patients with bone metastases. <i>Quality of Life Research</i> , 2014, 23, 527-532.	3.1	12
35	Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, e78-e89.	10.7	39
36	Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26. <i>Quality of Life Research</i> , 2013, 22, 369-378.	3.1	28

#	ARTICLE	IF	CITATIONS
37	Predictive factors for overall quality of life in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2013, 21, 1709-1716.	2.2	56
38	50 years of the EORTC and the central role of the EORTC Headquarters. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 3-12.	2.2	1
39	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 587-599.	1.4	12
40	Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1851-1858.	6.3	196
41	Reply to F. Janku et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e17-e18.	1.6	9
42	Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 2916-2923.	1.6	119
43	The practical impact of differential item functioning analyses in a health-related quality of life instrument. <i>Quality of Life Research</i> , 2009, 18, 1125-1130.	3.1	31
44	Patient-reported outcomes: Assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. <i>European Journal of Cancer</i> , 2009, 45, 347-353.	2.8	165
45	A simulation study provided sample size guidance for differential item functioning (DIF) studies using short scales. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 288-295.	5.0	110
46	Health-related quality of life and cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 9-11.	1.4	1
47	Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. <i>Lancet Oncology, The</i> , 2009, 10, 865-871.	10.7	519
48	The Trouble with Medical Journals. <i>European Journal of Cancer Care</i> , 2008, 17, 415-415.	1.5	0
49	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bac2/BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008, 44, 2178-2184.	2.8	39
50	The journey of health-related quality of life assessment. <i>Lancet Oncology, The</i> , 2008, 9, 906.	10.7	6
51	The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 1355-1363.	1.6	533
52	Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 5770-5776.	1.6	76
53	International Perspective on Health-Related Quality-of-Life Research in Cancer Clinical Trials: The European Organisation for Research and Treatment of Cancer Experience. <i>Journal of Clinical Oncology</i> , 2007, 25, 5082-5086.	1.6	89
54	The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care. <i>European Journal of Cancer</i> , 2006, 42, 55-64.	2.8	502

#	ARTICLE	IF	CITATIONS
55	Oncology: An Evidence-Based Approach. <i>European Journal of Cancer Care</i> , 2006, 15, 419-419.	1.5	0
56	Letter to the Editor. <i>Palliative Medicine</i> , 2006, 20, 59-61.	3.1	45
57	Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 1435-1442.	1.6	69
58	Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. <i>Journal of Clinical Oncology</i> , 2005, 23, 6881-6889.	1.6	601
59	Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. <i>Lancet Oncology, The</i> , 2005, 6, 287-294.	10.7	44
60	Health-related quality of life in patients with glioblastoma: a randomised controlled trial. <i>Lancet Oncology, The</i> , 2005, 6, 937-944.	10.7	288
61	Health-Related Quality of Life Parameters As Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3381-3388.	1.6	118
62	Is Baseline Quality of Life Useful for Predicting Survival With Hormone-Refractory Prostate Cancer? A Pooled Analysis of Three Studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 3877-3885.	1.6	65
63	What is the effect of systemic anticancer treatment on cognitive function?. <i>Lancet Oncology, The</i> , 2004, 5, 273-282.	10.7	91
64	Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2003, 21, 2982-2992.	1.6	72
65	Quality of Life in Good Prognosis Patients With Metastatic Germ Cell Cancer: A Prospective Study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). <i>Journal of Clinical Oncology</i> , 2003, 21, 1107-1118.	1.6	122
66	Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials—Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3502-3511.	1.6	230
67	Fatigue and Quality of Life: Lessons from the Real World. <i>Oncologist</i> , 2003, 8, 5-9.	3.7	234
68	The Cancer Patient and Quality of Life. <i>Oncologist</i> , 2002, 7, 120-125.	3.7	262
69	Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. <i>Statistics in Medicine</i> , 2002, 21, 3865-3884.	1.6	89